http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-600379-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d79362493392629399a529d819cdccd8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-42 |
| filingDate | 2010-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a16dd9f9869f9156c8ca694c9a928183 |
| publicationDate | 2014-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-600379-A |
| titleOfInvention | Morphinan derivatives for the treatment of drug overdose |
| abstract | Disclosed herein is the use of a compound of Formula I, wherein the variables are defined in the specification, in the treatment of drug toxicity or overdose in a subject. Specifically wherein the subject is an opioid experiences non-dependent opioid user. Additionally disclosed is the use of a first opioid receptor antagonist followed by use of a compound of Formula I, wherein the variables are defined in the specification, in the treatment of opioid toxicity or overdose in a subject. Specifically wherein said first opioid receptor antagonist is naloxone. Specifically wherein the compound is a malate salt. |
| priorityDate | 2009-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.